Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (DE:HTD)
FRANKFURT:HTD
Holding DE:HTD?
Track your performance easily
HTD Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€19.40 - €58.44
Previous Close€49.18
Volume0.00
Average Volume (3M)66.00
Market Cap
€5.14B
Enterprise Value€4.78B
Total Cash (Recent Filing)$380.34M
Total Debt (Recent Filing)$6.79M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Feb 12, 2025EPS Estimate
€0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding104,775,137
10 Day Avg. Volume0
30 Day Avg. Volume66
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)7.95
Price to Sales (P/S)8.53
Price to Cash Flow (P/CF)18.20
P/FCF Ratio18.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.61
Enterprise Value/Gross Profit10.05
Enterprise Value/Ebitda29.40
Forecast
1Y Price Target
€72.01Price Target Upside46.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Corcept Therapeutics News
PremiumCompany Announcements
Corcept Therapeutics Reports Strong Q3 Results and Positive Trial Outcomes
Bulls Say, Bears Say
Bulls Say
Drug Approval PathwayDazucorilant has Fast Track Designation from the FDA, allowing Corcept to have more interaction with the FDA to determine a path forward if survival benefit is maintained.
Financial PerformanceProduct sales revenue of Korlym for the quarter was $182.5M, representing a 48% YoY growth, exceeding both analyst expectations and the Street’s consensus.
Market PotentialThe prevalence results from the CATALYST study indicate a larger market than previously assumed, suggesting a significant opportunity for growth.
Bears Say
Clinical Trial DelaysCorcept announced at an Investor conference that the top-line data read-out from the Phase III ROSELLA trial for relacorilant in platinum-resistant ovarian cancer is now delayed to early 2025.
Clinical Trial FailuresDazucorilant misses on primary endpoint in the Phase II.
Legal And Regulatory RisksThe initiation of litigation in mid-June by Teva against Corcept that alleged anti-competitive practices could be seen as an admission by Teva that it has not been able to force meaningful generic substitution.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.02% Insiders
18.59% Mutual Funds
19.58% Other Institutional Investors
22.51% Public Companies and
Individual Investors
HTD FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was €19.40 and its highest was €58.44 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Currently, no data Available
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Feb 12, 2025 which is in 53 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Oct 30, 2024. The company reported €0.39 earnings per share for the quarter, beating the consensus estimate of €0.269 by €0.122.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is €0.36.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 104,775,140 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of €0.39 in its last earnings report, beating expectations of €0.269. Following the earnings report the stock price went down -14.779%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Among the largest hedge funds holding Corcept Therapeutics Inc.’s share is Royce & Associates LLC. It holds Corcept Therapeutics Inc.’s shares valued at 17M.
---
Corcept Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€72.01 (46.42% Upside)
€72.01 (46.42% Upside)
Blogger Sentiment
Bullish
DE:HTD Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $226.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.45%
12-Months-Change
Fundamentals
Return on Equity
25.53%
Trailing 12-Months
Asset Growth
32.02%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
HTD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strong positive outlook with significant growth in revenue and promising clinical trial results, particularly for relacorilant. However, there are ongoing legal challenges and some concerns regarding the statistical significance of certain clinical endpoints.Read More>---
HTD Stock 12 Month Forecast
Average Price Target
€72.01
▲(46.42% Upside)
Technical Analysis
Corcept Therapeutics
―
Axsome Therapeutics
―
Pacira Pharmaceuticals
―
Cytokinetics
―
ACADIA Pharmaceuticals
―
Best Analysts Covering HTD
1 Year
1 Year Success Rate
14/15 ratings generated profit
1 Year Average Return
+45.77%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +45.77% per trade.
---